Japan’s Nagoya University Establish Bio Venture Company To Develop Arteriosclerosis Drugs
This article was originally published in PharmAsia News
Nagoya City University established the venture company Hyks Laboratories to develop drugs to treat and prevent arteriosclerosis. Utilizing funds from the Japan Science and Technology Agency, the university's school of medicine has been focusing on research and development of a drug to increase blood's high-density lipoproteins count, Based on the research results, the company also plans to partner with pharmaceutical companies to conduct basic research on HDL functions. Cerebral vascular diseases account for one third of the total deaths in Japan and prevention and treatment have become a major topic for medical researchers and pharmaceutical companies. (Click here for more - Japanese language
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.